Hepatitis C and hepatocellular carcinoma

• Published in: Annals of hepatology Vol. 9 Suppl; pp. 119 - S122
• Main Author: Fassio, Eduardo
• Format: Journal Article
• Language: English
• Published: Mexico Elsevier 2010
• Subjects: Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - epidemiology; Carcinoma, Hepatocellular - virology; Cirrhosis; Coinfection; Disease Progression; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - epidemiology; Hepatocarcinoma; Humans; Incidence; Incidence of hepatocarcinoma; Interferon; Latin America - epidemiology; Liver Cirrhosis - virology; Liver Neoplasms - diagnosis; Liver Neoplasms - epidemiology; Liver Neoplasms - virology; Mass Screening - methods; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Risk factors for hepatocarcinoma; Latin America
• ISSN: 1665-2681
• DOI: 10.1016/S1665-2681(19)31736-3

Chronic hepatitis C virus infection is a well-recognized risk factor for occurrence of hepatocellular carcinoma (HCC). In Europe, Oceania and America, chronic hepatitis C and alcoholic cirrhosis are the main risk factors for HCC. In Latin America, a few retrospective and one prospective study have also shown the predominant role played by hepatitis C in this setting. Furthermore, the incidence of HCC has been increasing in industrialized countries in the last decades; partially as a consequence of the increase in HCV-related cirrhosis (as the long-term sequel of the peak of infections occurring 2-4 decades ago). The main risk factor for HCC development in patients with hepatitis C is the presence of cirrhosis. Among patients with hepatitis C and cirrhosis, the annual incidence rate of HCC ranges between 1-8%, being higher in Japan (4-8%) intermediate in Italy (2-4%) and lower in USA (1.4%). Some studies have also found that HCC may be the first complication to develop and the more frequent cause of death in the compensated HCV-associated cirrhosis. Other risk factors for HCC occurrence are older age at infection, male gender, decreased platelet count, esophageal varices, presence of porphyria cutanea tarda, liver steatosis or diabetes, infection with genotype 1b, coinfection with hepatitis B virus or with HIV and chronic alcoholism. Many studies and also meta-analysis have reported that antiviral therapy based on interferon may reduce the incidence of HCC in chronic hepatitis C, especially in patients with sustained virologic response. Patients with HCV-related cirrhosis should undergo surveillance for HCC.